Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2020.593823
Keywords
effector-triggered immunity; effector-mediated immunity; Legionella pneumophila; innate immunity; macrophage
Categories
Funding
- NIH NIGMS COBRE Research Project Grant [P20GM130448]
- NIH Kansas-INBRE Postdoctoral Fellowship [P20GM103418]
- U.S. Department of Agriculture Research Service project [3020-43440-001-00D]
- Kansas State University
Ask authors/readers for more resources
The article discusses the immune responses mediated by effector proteins in Gram-negative bacterial pathogens and the potential future of developing new drugs using effector proteins.
Many Gram-negative bacterial pathogens employ translocated virulence factors, termed effector proteins, to facilitate their parasitism of host cells and evade host anti-microbial defenses. However, eukaryotes have evolved to detect effector-mediated virulence strategies through a phenomenon termed effector-triggered immunity (ETI). Although ETI was discovered in plants, a growing body of literature demonstrates that metazoans also utilize effector-mediated immunity to detect and clear bacterial pathogens. This mini review is focused on mechanisms of effector-mediated immune responses by the accidental human pathogen Legionella pneumophila. We highlight recent advancements in the field and discuss the future prospects of harnessing effectors for the development of novel therapeutics, a critical need due to the prevalence and rapid spread of antibiotic resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available